Evidence map›Paper›PMID 41031891›Full record

ArticleThe Journal of clinical investigation2025

SOX9 drives a stem-like transcriptional state and platinum resistance in high-grade serous ovarian cancer.

Alexander J Duval, Fidan Seker-Polat, Magdalena Rogozinska, Meric Kinali, Ann E Walts, Ozlem Neyisci, Yaqi Zhang, Zhonglin Li, Edward J Tanner, Allison E Grubbs and 3 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexander J DuvalDepartment of Obstetrics and Gynecology and.
Fidan Seker-PolatDepartment of Obstetrics and Gynecology and.
Magdalena RogozinskaDepartment of Obstetrics and Gynecology and.
Meric KinaliDepartment of Obstetrics and Gynecology and.
Ann E WaltsDepartment of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Ozlem NeyisciDepartment of Obstetrics and Gynecology and.
Yaqi ZhangDepartment of Obstetrics and Gynecology and.
Zhonglin LiDepartment of Obstetrics and Gynecology and.
Edward J TannerDepartment of Obstetrics and Gynecology and.
Allison E GrubbsDepartment of Obstetrics and Gynecology and.
Sandra OrsulicDepartment of Obstetrics and Gynecology, David Gefen School of Medicine, UCLA, Los Angeles, California, USA.
Daniela MateiDepartment of Obstetrics and Gynecology and.
Mazhar AdliDepartment of Obstetrics and Gynecology and.

Funding

Chemo-mediated transcriptional reprogramming in ovarian cancerR01CA267544 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ADLI, MAZHAR · 2022 to 2025
$2.2M
BLRD VA I01 BX006020NCI NIH HHS R01 CA267544
6 · The paper itself

Abstract

Chemotherapy resistance remains a formidable challenge to the treatment of high-grade serous ovarian cancer (HGSOC). The drug-tolerant cells may originate from a small population of inherently resistant cancer stem cells (CSCs) in primary tumors. In contrast, sufficient evidence suggests that drug tolerance can also be transiently acquired by nonstem cancer cells. Regardless of the route, key regulators of this plastic process are poorly understood. Here, we utilized multiomics, tumor microarrays, and epigenetic modulation to demonstrate that SOX9 is a key chemo-induced driver of chemoresistance in HGSOC. Epigenetic upregulation of SOX9 was sufficient to induce chemoresistance in multiple HGSOC lines. Moreover, this upregulation induced the formation of a stem-like subpopulation and significant chemoresistance in vivo. Mechanistically, SOX9 increased transcriptional divergence, reprogramming the transcriptional state of naive cells into a stem-like state. Supporting this, we identified a rare cluster of SOX9-expressing cells in primary tumors that were highly enriched for CSCs and chemoresistance-associated stress gene modules. Notably, single-cell analysis showed that chemo treatment results in rapid population-level induction of SOX9 that enriches for a stem-like transcriptional state. Altogether, these findings implicate SOX9 as a critical regulator of early steps of transcriptional reprogramming that lead to chemoresistance through a CSC-like state in HGSOC.

Indexed as

Cystadenocarcinoma, SerousDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticNeoplasm ProteinsNeoplastic Stem CellsOvarian NeoplasmsSOX9 Transcription FactorAnimalsCell Line, TumorEpigenesis, GeneticFemaleHumansMiceNeoplasm ProteinsSOX9 protein, humanSOX9 Transcription FactorCancerEpigeneticsOncologyStem cellsTranscription

Identifiers

PMID41031891
PMCPMC12483608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.